Nektar Therapeutics
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2009 | $39.7M | $23.3M | $16.4M | $10.3M |
| FY2010 | $-55.9M | $-87.3M | $31.5M | $17.4M |
| FY2011 | $-113.7M | $-123.5M | $9.7M | $18.9M |
| FY2012 | $-129.8M | $-140.3M | $10.6M | $16.2M |
| FY2013 | $-38.5M | $-42.6M | $4.1M | $17.7M |
| FY2014 | $-142.0M | $-152.0M | $10.0M | $17.0M |
| FY2015 | $-73.1M | $-84.3M | $11.2M | — |
| FY2016 | $-117.0M | $-123.4M | $6.4M | — |
| FY2017 | $-80.4M | $-90.1M | $9.7M | — |
| FY2018 | $718.2M | $704.0M | $14.2M | — |
| FY2019 | $-328.7M | $-355.0M | $26.3M | — |
| FY2020 | $-313.3M | $-320.5M | $7.3M | — |
| FY2021 | $-412.7M | $-427.6M | $15.0M | — |
| FY2022 | $-304.0M | $-309.7M | $5.7M | — |
| FY2023 | $-192.6M | $-193.5M | $865.0K | — |
| FY2024 | $-175.7M | $-177.2M | $1.5M | — |
| FY2025 | $-208.5M | $-208.7M | $171.0K | — |